A new manuscript from the IGNITE Pragmatic Trials Network has been published in JAMA Network Open, describing the primary results of the GUARDD-US study. GUARDD-US is a randomized controlled trial examining the impact of returning APOL1 genetic risk results to ...
Precision Medicine and Immunotherapy: The new frontiers in cancer care? Friday, November 10 | 11 a.m. ET | Online Speaker: Ugwuji Maduekwe, MD, MMSc, MPH Dr. Maduekwe will present an exploration of the dispersion of new therapies in the care of cancer that are inequitably distributed and solutions to closing these gaps. To learn more […]
Immune (check point) Related Adverse Events Wednesday, February 28 | 12 p.m. ET | Online Speaker: Frances Collichio, MD, Professor of Medicine, UNC Chapel Hill Dr. Collichio will review the common and uncommon side effects of immune check point inhibitors. She will also discuss the relatively new concept of delayed immune related events. To learn […]
GMKB